Clinical Trial Update: Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer [NA]

View source ↗

Summary

The trial evaluating spot-scanning based hypofractionated proton therapy for low- and intermediate-risk prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: EBG MedAustron GmbH | Conditions: Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer | NA | Status: TERMINATED